1.
Bioorg Med Chem Lett
; 29(3): 487-490, 2019 02 01.
Artículo
en Inglés
| MEDLINE
| ID: mdl-30553736
RESUMEN
To explore the application of photoremovable protecting groups (PPGs) in the field of combination chemotherapy, we designed and synthesized a photoresponsive hybrid prodrug 4 that bearing both doxorubicin (DOX) and combretastatin A4 (CA4). Light triggered drug release investigation found that DOX release was mainly accomplished by 405â¯nm light while CA4 release was mainly triggered by 365â¯nm light, i.e., prodrug 4 exhibited a quasi-sequential release behavior when a sequential light irradiation strategy was applied. Cell viability evaluation confirmed the increased cytotoxicity of prodrug 4 compared with individual drugs towards MDA-MB-231cells, indicating that a synergistic effect was achieved.